Although intended for the lungs, many drugs are not given via the airway because drug properties make it too difficult to formulate for direct to lung delivery. Given systemically, these drugs often produce unwanted and potentially life-threatening side effects. To get around this, companies have tried to use microcapsules, carriers, and other agents to try to dose drugs direct to the lungs, but these other delivery agents often produce their own problems. Using its proprietary technology, TFF can generate dry powder inhaler versions of these drugs using nothing but the drug itself and approved lung friendly ingredients. This means that drugs of all types â small molecules, biologics, even combinations â can be dosed direct to the lungs with few, if any, side effects. Source
No articles found.
LivaNova is a global medical technology company built on decades of experience and...
LivaNova is a global medical technology company...
BelleIQ operates ALLIES, an online marketplace selling health & wellness products ...
BelleIQ operates ALLIES, an online marketplace ...
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused o...
BioXcel Therapeutics, Inc. is a clinical stage ...
At ACADIA (NASDAQ: ACAD), we share a passion for improving the lives of patients w...
At ACADIA (NASDAQ: ACAD), we share a passion fo...
Join the National Investor Network and get the latest information with your interests in mind.